Objective : The study aim was to compare the relationship between serum anti-Mill lcrian hormone (AMH) levels and other markers of ovarian reserve and to determine its predictive value. Design: prospective randomized trial. Setting : Alexandria University and IVF-ICSI Madina private center . Patients : 60 infertile women under going IVF-ICSI programmes.
INTRODUCTION

Anti-Mullerian hormone (AMH) is a glycoprotein
hormone that belongs to the transforming growth factor superfamily "' and is chiefly expressed in the fetal testis to drive differentiation of the mammalian reproductive tract"'. In women, granulosa cell production of AMH (3) is barely delectable at birth ( ' and reaches the highest values after puberty *■ \ During adulthood, although AMH continues to be expressed at basal and similar levels by both the Sertoli and granulosa cells ®\ its biological role is poorly understood.
Basic research data obtained from the adult ovary indicate that AMH is likely to be involved in the regulation of follicular stcroidogencsis. Expcrimcnls conducted in animals suggest that AMH reduces aromatase activity and the number of LH receptors in FSH-stimulated granulosa cells* ', and also influences testosterone production by theca cells (7 \ In addition, growing evidence indicates that AMH is mainly expressed in pre-antral and early antral follicles (8 
MATERIALS & METHODS
Subjects
The study Step-up or step-down protocols were decided according to subsequent ultrasound controls.
In cases of less than two growing follicles or a serum E 2 level of less than 300 pg/mL on cycle day 14, treatment cycle was cancelled.
After more than three follicles larger than 18 mm were observed, 10,000 IU of hCG was administered intramuscularly, and 36 hours later follicles were aspirated under general anesthesia. Mature oocytes were retrieved from follicular fluid and placed in culture medium (G-l TM version 3; Vitrolife, Goteborg, Sweden) prepared for ICSI and blastocyst development media (G-2 TM version 3; Vitrolife). and idiopathic (12 couples). The ages of the female patients were between 24 and 39 years. The mean infertility period was 9 ± 3.9 years, and the mean body mass index of female patients was in the normal range (sec Table) . Ovarian reserve was assessed by basal hormone levels on cycle day 3.
Treatment was started with a mean dose of 244 ± 59 IU/day of rccombinanl FSH (150-300 1U); a total dose of 2410 ± 978 IU/day (1050-5400 IU) was reached. A mean period of 9 ± 2 days (5-14) was spent on the treatment. The results of the study were evaluated according to the number of growing follicles, oocytcs, and mature oocylcs retrieved (see Table I ). Fifteen couples ended in pregnancy. Two of them continued as twin pregnancies, and eight as singletons. Three pregnancies were aborted, and two were biochemical pregnancies.
The study group was divided into two subgroups according to the number of oocytcs retrieved. Patients with an oocytc count of five or more were considered good rcspondcrs and less than five as poor responders. All parameters were compared for these two groups. Characteristics such as age, infertility period, and body mass index were similar between good and poor responders.
Good responders had a mean beginning dose of 249 ± 58 IU/day, and a total dose of 2363 ± 969 IU was reached in 8±2 days. Poor responders had a mean starting dose of 231 ± 62 IU/day, and a total dose of 255011041 IU was reached in a mean period of 9±1 days. These parameters were statistically alike.
Parameters such as basal scrum FSH, inhibin B and E2 levels were also not statistically different.
Meanwhile, the difference between scrum AMH levels, maximum E2 levels, antral follicle count, hCG day follicle counts, and mature oocytc counts were statistically significant (see Table I ).
The main parameter of the study, AMH, was found to be considerably higher in good responders; mean level was 0.67±0.41pg/mL. The AMH level was 0.15±0.1 lpg/mL in poor responders (P<.001). 
CONCLUSIONS
our data indicate that early follicular AMH levels can offer a contribution to the serum markers currently being used for evaluating ovarian reserve, but AMH levels will not reveal the possibility of pregnancy.
